title: Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis.
authors.forename: Julien
authors.initials: J
authors.lastname: Haroche
authors.forename: Zahir
authors.initials: Z
authors.lastname: Amoura
authors.forename: Frédéric
authors.initials: F
authors.lastname: Charlotte
authors.forename: Juan
authors.initials: J
authors.lastname: Salvatierra
authors.forename: Bertrand
authors.initials: B
authors.lastname: Wechsler
authors.forename: Carlos
authors.initials: C
authors.lastname: Graux
authors.forename: Nicole
authors.initials: N
authors.lastname: Brousse
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Piette
mesh_terms: D000328:Adult; D001549:Benzamides; D031249:Erdheim-Chester Disease / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000378:metabolism*
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D020797:Receptor, Platelet-Derived Growth Factor beta